Articles Tagged With:
-
Tenecteplase vs. Alteplase for Treatment of Acute Ischemic Stroke: It Is Time to Make the Change
Since 1996, when the U.S. Food and Drug Administration approved the use of intravenous alteplase for the treatment of acute ischemic stroke, there has been a steady increase in the adoption of both intravenous thrombolysis as well as endovascular thrombolysis and mechanical thrombectomy for the treatment of patients with acute ischemic stroke and large vessel occlusion. There now is extensive experience with the use of tenecteplase for the treatment of acute ischemic stroke. It has been shown to be equally efficacious, with a similar risk profile as alteplase.
-
Radiosurgery vs. Watch-and-Wait Approach for Newly Diagnosed Vestibular Schwannoma
Vestibular schwannoma is the most common tumor of the cerebellopontine angle. There is controversy regarding the management of these benign tumors with up-front radiosurgery vs. observation, especially for those that are small- to medium-sized with minimal symptoms. Recent evidence suggests that up-front radiosurgery may reduce tumor volume at four-year follow-up.
-
Nitrous Oxide-Induced Neuropathy
Nitrous oxide-induced neuropathy presents with a rapidly progressive sensorimotor neuropathy that may mimic Guillain-Barré syndrome. The pattern of clinical weakness and progression, as well as electrophysiological features, can help to rapidly distinguish the two disorders.
-
Comparison of the Efficacy of Rituximab vs. Ocrelizumab in the Treatment of Relapsing Multiple Sclerosis
Rituximab is an anti-CD20 chimeric monoclonal antibody used off-label to treat multiple sclerosis (MS). Ocrelizumab is a humanized monoclonal anti-CD20 monoclonal antibody that is Food and Drug Administration-approved for the treatment of MS. In this observational cohort study, the authors were not able to demonstrate noninferiority of rituximab compared to ocrelizumab because of a significantly lower relapse rate in the ocrelizumab-treated group.
-
Burning Down the House: Climate Change Drives Emerging Infections
The connection between emerging infections and climate change has gone from theoretical discussions in the past few years to an evidence-based phenomenon happening in real time. That said, there are multiple converging factors, and attributing all emerging infections to global warming is too broad a stroke to explain a complex issue.
-
CAUTIs: What to Do, What Not to Do
New compendium recommendations by the nation’s leading infection control groups on catheter-associated urinary tract infections (CAUTIs) emphasize that, in most cases, screening for asymptomatic bacteriuria does more harm than good.
-
What Is in Your Laundry? The Threat of Mucormycosis
Even pressed and folded, so-called “hygienically clean” hospital laundry can harbor fungal pathogens, sometimes in sufficient number to cause fatal mucormycosis infections in high-risk patients, outbreak investigators reported at the 2023 conference of the Association for Professionals in Infection Control and Epidemiology.
-
Misinformation: The Many-Headed Hydra
Social media platforms have become the Wild West of misinformation, and current indications suggest this is going to continue and possibly expand, said Donna Nucci, RN, MS, CIC, director of infection prevention, Yale New Haven Health.
-
Statins Might Lower Risk of Recurrent Stroke
Patients in Denmark who suffered an intracerebral hemorrhage and were taking cholesterol-lowering medication were less likely to experience another stroke.
-
Preventing and Reversing Cardiovascular Disease Through Lifestyle Modification
Cardiovascular disease (CVD) is the leading cause of death globally and in the United States. Identifying and targeting cardiovascular risk factors is essential for the prevention and long-term management of CVD. Traditionally, factors for the onset and progression of CVD were thought to be mostly genetic. It is now well established that several of these factors are lifestyle mediated. Behavioral changes significantly influence the interplay between a healthy lifestyle and the genetic risk of heart disease. To further understand the challenges with preventing and reversing CVD, providers need to consider the alarming prevalence of risk factors among the U.S. population.